로딩 중…
StockDiggingStockDigging

Becton, Dickinson and Company

BDX· NYSE
$170.60+0.28%
2026-08-05

Financials

Valuation Metrics

Becton, Dickinson and Company's Market Cap is $47.01B. At end of 2025 it was $43.49B. Ranked #342 of 3,112 in US market (top 11%), #248 of 1,667 on NYSE (top 15%), #17 of 206 in Health Care Equipment & Services (top 8%) by Market Cap.

Investment Metrics(as of 2026-08-05)

MetricValue
Size
Market Cap$47.01B
Revenue$21.36B
Net Income$1.14B
Total Assets$50.83B
Net Assets$24.13B
Employees70,000
Value
P/E41.31x
P/B1.95x
P/S2.20x
EV/EBITDA13.55x
FCF Yield6.68%
Profitability
ROE4.72%
ROA2.24%
Op. Margin10.61%
Revenue Growth-10.58%
Earnings Growth-200.97%
Financial Health
Debt Ratio110.63%
Total Debt$17.28B
FCF$3.14B
Cash$813M
Current Ratio0.94x
Net Debt/EBITDA3.52x
Dividend
Div. Yield2.52%
Div. Growth9.92%
Performance
1Y Return24.02%
1M Return9.68%
From 52W High-8.94%
1Y MDD-24.10%
Trading
Volume1,842,626 shares
Trading Value$313M
Per Share
EPS$6.16
BPS$88.69

Company Info

CEO Mr. Thomas E. Polen Jr.
Employees 70,000
HQ Franklin Lakes, United States

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.